Repurposing itraconazole as a treatment for advanced prostate cancer: a noncomparative randomized phase II trial in men with metastatic castration-resistant prostate cancer.

BACKGROUND The antifungal drug itraconazole inhibits angiogenesis and Hedgehog signaling and delays tumor growth in murine prostate cancer xenograft models. We conducted a noncomparative, randomized, phase II study evaluating the antitumor efficacy of two doses of oral itraconazole in men with metastatic prostate cancer. PATIENTS AND METHODS We randomly assigned 46 men with chemotherapy-naïve metastatic castration-resistant prostate cancer (CRPC) to receive low-dose (200 mg/day) or high-dose (600 mg/day) itraconazole until disease progression or unacceptable toxicity. The primary endpoint was the prostate-specific antigen (PSA) progression-free survival (PPFS) rate at 24 weeks; a 45% success rate in either arm was prespecified as constituting clinical significance. Secondary endpoints included the progression-free survival (PFS) rate and PSA response rate (Prostate Cancer Working Group criteria). Exploratory outcomes included circulating tumor cell (CTC) enumeration, serum androgen measurements, as well as pharmacokinetic and pharmacodynamic analyses. RESULTS The high-dose arm enrolled to completion (n = 29), but the low-dose arm closed early (n = 17) because of a prespecified futility rule. The PPFS rates at 24 weeks were 11.8% in the low-dose arm and 48.0% in the high-dose arm. The median PFS times were 11.9 weeks and 35.9 weeks, respectively. PSA response rates were 0% and 14.3%, respectively. In addition, itraconazole had favorable effects on CTC counts, and it suppressed Hedgehog signaling in skin biopsy samples. Itraconazole did not reduce serum testosterone or dehydroepiandrostenedione sulfate levels. Common toxicities included fatigue, nausea, anorexia, rash, and a syndrome of hypokalemia, hypertension, and edema. CONCLUSION High-dose itraconazole (600 mg/day) has modest antitumor activity in men with metastatic CRPC that is not mediated by testosterone suppression.

[1]  David C. Smith,et al.  Cabozantinib in patients with advanced prostate cancer: results of a phase II randomized discontinuation trial. , 2013, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[2]  Kurt Miller,et al.  Increased survival with enzalutamide in prostate cancer after chemotherapy. , 2012, The New England journal of medicine.

[3]  Jun O. Liu,et al.  Itraconazole inhibits angiogenesis and tumor growth in non-small cell lung cancer. , 2011, Cancer research.

[4]  A. Armstrong,et al.  Phase II randomized, double-blind, placebo-controlled study of tasquinimod in men with minimally symptomatic metastatic castrate-resistant prostate cancer. , 2011, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[5]  P. Troncoso,et al.  Expression of hedgehog pathway components in prostate carcinoma microenvironment: shifting the balance towards autocrine signalling , 2011, Histopathology.

[6]  Arturo Molina,et al.  Abiraterone and increased survival in metastatic prostate cancer. , 2011, The New England journal of medicine.

[7]  E. Antonarakis,et al.  Expanding treatment options for metastatic prostate cancer. , 2011, The New England journal of medicine.

[8]  P. Carmeliet,et al.  Molecular mechanisms and clinical applications of angiogenesis , 2011, Nature.

[9]  D. Hanahan,et al.  Hallmarks of Cancer: The Next Generation , 2011, Cell.

[10]  C. Rudin,et al.  Phase I Trial of Hedgehog Pathway Inhibitor Vismodegib (GDC-0449) in Patients with Refractory, Locally Advanced or Metastatic Solid Tumors , 2011, Clinical Cancer Research.

[11]  Maneesh Jain,et al.  Angiogenesis inhibitors in prostate cancer therapy. , 2010, Discovery medicine.

[12]  J. Machiels,et al.  Prednisone plus cabazitaxel or mitoxantrone for metastatic castration-resistant prostate cancer progressing after docetaxel treatment: a randomised open-label trial , 2010, The Lancet.

[13]  E. Heath,et al.  Angiogenesis inhibitors in the treatment of prostate cancer , 2010, Journal of hematology & oncology.

[14]  P. Kantoff,et al.  Sipuleucel-T immunotherapy for castration-resistant prostate cancer. , 2010, The New England journal of medicine.

[15]  Jun O. Liu,et al.  Itraconazole, a commonly used antifungal that inhibits Hedgehog pathway activity and cancer growth. , 2010, Cancer cell.

[16]  Jun O. Liu,et al.  Cholesterol trafficking is required for mTOR activation in endothelial cells , 2010, Proceedings of the National Academy of Sciences.

[17]  T. Pieber,et al.  Aldosterone and arterial hypertension , 2010, Nature Reviews Endocrinology.

[18]  M. Cohn,et al.  Sonic hedgehog controls growth of external genitalia by regulating cell cycle kinetics , 2009, Nature communications.

[19]  Paul Mathew,et al.  Department of Defense prostate cancer clinical trials consortium: a new instrument for prostate cancer clinical research. , 2009, Clinical genitourinary cancer.

[20]  Mitch Dowsett,et al.  Phase I clinical trial of a selective inhibitor of CYP17, abiraterone acetate, confirms that castration-resistant prostate cancer commonly remains hormone driven. , 2008, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[21]  Susan Halabi,et al.  Design and end points of clinical trials for patients with progressive prostate cancer and castrate levels of testosterone: recommendations of the Prostate Cancer Clinical Trials Working Group. , 2008, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[22]  F. Saad,et al.  A phase 3 randomized controlled trial of the efficacy and safety of atrasentan in men with metastatic hormone‐refractory prostate cancer , 2007, Cancer.

[23]  C. Chong,et al.  New uses for old drugs , 2007, Nature.

[24]  C. Parker,et al.  Bone-targeted radium-223 in symptomatic, hormone-refractory prostate cancer: a randomised, multicentre, placebo-controlled phase II study. , 2007, The Lancet. Oncology.

[25]  Jun O. Liu,et al.  Inhibition of angiogenesis by the antifungal drug itraconazole. , 2007, ACS chemical biology.

[26]  H. Scher,et al.  Circulating Tumor Cell Analysis in Patients with Progressive Castration-Resistant Prostate Cancer , 2007, Clinical Cancer Research.

[27]  I. Tannock,et al.  Docetaxel plus prednisone or mitoxantrone plus prednisone for advanced prostate cancer. , 2004, The New England journal of medicine.

[28]  E. Small,et al.  Antiandrogen withdrawal alone or in combination with ketoconazole in androgen-independent prostate cancer patients: a phase III trial (CALGB 9583). , 2004, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[29]  W. Bagg,et al.  Cushing's Syndrome Due to Interaction Between Inhaled Corticosteroids and Itraconazole , 2004, The Annals of pharmacotherapy.

[30]  R. W. Hansen,et al.  The price of innovation: new estimates of drug development costs. , 2003, Journal of health economics.

[31]  M. Christian,et al.  [New guidelines to evaluate the response to treatment in solid tumors]. , 2000, Bulletin du cancer.

[32]  M. van Glabbeke,et al.  New guidelines to evaluate the response to treatment in solid tumors , 2000, Journal of the National Cancer Institute.

[33]  M Van Glabbeke,et al.  New guidelines to evaluate the response to treatment in solid tumors. European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada. , 2000, Journal of the National Cancer Institute.

[34]  E. Messing,et al.  High-dose ketoconazole in advanced hormone-refractory prostate cancer: endocrinologic and clinical effects. , 1989, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.